(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on custom impurity synthesis, advanced isolation and compliance testing, driven by biosimilars, CRO outsourcing, stability studies and genotoxic impurity analysis.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Pharmaceutical Impurity Synthesis and Isolation Services Market to Reach $1.76 Billion by 2030
The global pharmaceutical impurity synthesis and isolation services market is experiencing strong growth as pharmaceutical and biotechnology companies increase their focus on drug safety, quality control and regulatory compliance. The market is projected to expand from $1.19 billion in 2025 to $1.29 billion in 2026, representing a compound annual growth rate (CAGR) of 8.4%.
Historical market growth has been supported by expanding pharmaceutical manufacturing, greater regulatory scrutiny and the wider adoption of chromatographic methods for impurity analysis. Demand has also increased as drug developers seek specialized capabilities to identify, characterize and control impurities arising during product development, manufacturing, storage and degradation.
Looking ahead, the pharmaceutical impurity synthesis and isolation services market is forecast to reach $1.76 billion by 2030, growing at a CAGR of 8.1%. Key growth drivers include the development of advanced hyphenated analytical techniques, increased synthesis of metabolites and degradation products, rising outsourcing to contract research organizations, and broader use of stability studies. Regulatory requirements surrounding impurity profiling are also expected to create sustained demand for specialized analytical and purification services.
Major pharmaceutical impurity synthesis and isolation services market trends include growing demand for custom impurity synthesis, advanced isolation techniques and analytical services designed to support regulatory submissions. Drug development and quality control programs are increasingly integrating stability analysis and genotoxic impurity testing, creating opportunities for service providers with comprehensive synthesis, separation, characterization and documentation capabilities.
Rising biosimilar production is expected to be a significant catalyst for market expansion. Patent expirations for reference biologic products are enabling manufacturers to develop more affordable alternatives and improve patient access. Impurity synthesis and isolation services support these programs by helping manufacturers identify, characterize and control process- and product-related impurities while meeting stringent safety, quality and regulatory requirements.
For example, the African Development Bank reported in March 2025 that the new XpandC facility in Cote d'Ivoire is expected to increase annual biosimilar production capacity from 3 million doses to 7.65 million doses by 2032. The facility is also set to introduce two additional biosimilars, highlighting the continued expansion of biologic manufacturing capacity and the corresponding need for advanced impurity analysis services.
Innovation in high-purity reference standards is further shaping the market. In July 2025, Bangladesh-based Advent Pharma Limited launched a high-purity reference standard for the lidocaine impurity 1,4-Bis(2,6-dimethylphenyl) piperazine-2,5-dione. Featuring purity of at least 97% and comprehensive analytical documentation, the reference standard supports analytical method validation, stability testing and regulatory filings aligned with ICH Q3A/B and Q2 guidelines.
Strategic acquisitions are also expanding technical capabilities across the pharmaceutical impurity testing and isolation sector. In June 2024, UK-based CatSci Ltd acquired Reach Separations for an undisclosed amount. The transaction added advanced supercritical fluid chromatography and high-performance liquid chromatography capabilities to CatSci's portfolio, along with expertise in chiral and achiral separation and scalable impurity isolation. The acquisition strengthened CatSci's end-to-end analytical, purification and manufacturing services while supporting greater operational efficiency and service capacity.
North America was the largest regional market for pharmaceutical impurity synthesis and isolation services in 2025, supported by established pharmaceutical research infrastructure, extensive drug development activity and rigorous quality standards. Asia-Pacific is expected to be the fastest-growing region during the forecast period as pharmaceutical manufacturing, biosimilar development and outsourced research services continue to expand. Regions covered include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Service: Synthesis Services; Isolation Services; Analytical Services
2) By Impurity Type: Organic Impurities; Inorganic Impurities; Residual Solvents
3) By Technique: Chromatography; Spectroscopy; Crystallization; Hyphenated Techniques; Other Techniques
4) By Application: Drug Development; Commercial Manufacturing; Quality Control; Regulatory Compliance
5) By End User: Biotech And Pharmaceutical Companies; Contract Research Organizations (CRO); Other End Users
Subsegments:
1) By Synthesis Services: Custom Impurity Synthesis; Stable Isotope-Labeled Impurity Synthesis; Process-Related Impurity Synthesis; Degradation Product Synthesis; Metabolite Synthesis
2) By Isolation Services: Isolation Of Process Impurities; Isolation Of Degradation Impurities; Preparative Chromatography-Based Isolation; Crystallization-Based Isolation; Flash Chromatography Isolation
3) By Analytical Services: Impurity Profiling; Structural Elucidation; Quantitative Analysis; Genotoxic Impurity Analysis; Stability Studies
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment